



Appln. No. 10/634,682

**Amendments to the Claims:**

1. (Currently Amended) A pyrimidinyl compound  
 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]  
 amino]benzonitrile, a *N*-oxide, an addition salt, a quaternary amine or a stereochemically  
 isomeric form thereof, said compound having the following structure:



2. (Currently Amended) A pyrimidinyl compound ~~according to claim 1~~ wherein the  
 pyrimidinyl compound is 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-  
 pyrimidinyl]amino]benzonitrile, said compound having the following structure:



3. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically  
 acceptable carrier and ~~a therapeutically active~~ an effective amount of a pyrimidinyl  
 compound according to ~~claims 1 or 2~~ any of claims 1 or 2.
4. (Currently Amended) A combination comprising a pyrimidinyl compound according to  
~~claims 1 or 2~~ any of claims 1 or 2 and an antiretroviral compound, wherein said antiretroviral  
 compound comprises at least one of a nucleoside reverse transcriptase inhibitor, a non-  
 nucleoside reverse transcriptase inhibitor, a TIBO compound, an  $\alpha$ -APA compound, a TAT-  
 inhibitor, a protease inhibitor, an immunomodulating agent, and mixtures thereof.
5. (Original) A combination according to claim 4, wherein said nucleoside reverse  
 transcriptase inhibitor comprises at least one of zidovudine (3'-azido-3'-deoxythymidine,

Appln. No. 10/634,682

AZT), didanosine (dideoxy inosine; ddI), zalcitabine (dideoxycytidine, ddC), lamivudine (3'-thia-2'-3'-dideoxycytidine, 3TC), and mixtures thereof.

6. (Currently Amended) A combination according to claim 4, wherein said non-nucleoside reverse transcriptase inhibitors comprises at least one of suramine, pentamidine, thymopentin, castanospermine, efavirenz, ~~dextran~~ (dextran sulfate), foscarnet-sodium (trisodium phosphono formate), nevirapine (11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b : 2',3'-e][1,4]diazepin-6-one), tacrine (tetrahydroaminoacridine), and mixtures thereof.

7. (Original) A combination according to claim 4, wherein said TIBO compound comprises (S)-8-chloro-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo-[4,5,1-jk][1,4]benzodiazepine-2(1H)-thione.

8. (Original) A combination according to claim 4, wherein said  $\alpha$ -APA compound comprises  $\alpha$ -(2-nitro-phenyl)amino]-2,6-dichlorobenzene-acetamide.

9. (Original) A combination according to claim 4, wherein said protease inhibitor comprises at least one of indinavir, ritanovir, saquinovir, ABT-378, and mixtures thereof.

10. (Original) A combination according to claim 4, comprising at least one of RO-5-3335, levamisole, and mixtures thereof.

11. (Original) A combination according to claim 5, further comprising a pharmaceutically acceptable carrier.


12. (Original) A combination according to claim 6, further comprising a pharmaceutically acceptable carrier.

13. (Original) A combination according to claim 7, further comprising a pharmaceutically acceptable carrier.

14. (Original) A combination according to claim 8, further comprising a pharmaceutically acceptable carrier.

Appln. No. 10/634,682

15. (Original) A combination according to claim 9, further comprising a pharmaceutically acceptable carrier.
16. (Original) A combination according to claim 10, further comprising a pharmaceutically acceptable carrier.
17. (Original) A combination according to claim 4 wherein said pyrimidinyl compound and said antiretroviral compound are combined in a single preparation.
18. (Original) A combination according to claim 17, further comprising a pharmaceutically acceptable carrier.
19. (Original) A process for preparing a compound as claimed in claim 2, comprising reacting a compound of formula



with  $\text{NH}_3$  in the presence of a reaction inert solvent.

20. (Original) A process according to claim 19, wherein said reacting is performed in the presence of a base.
21. (Currently Amended) A method of treating subjects suffering from HIV (Human Immunodeficiency Virus) infection comprising administering to the subject ~~a therapeutically~~ an effective amount of a compound according to claims 1 or 2.
22. (Currently Amended) A method of treating subjects suffering from HIV (Human Immunodeficiency Virus) infection comprising administering to the subject a ~~therapeutically~~ an effective amount of a combination according to claim 4.
23. (New) A pyrimidinyl compound as claimed in claim 1, wherein the compound is an addition salt of 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile.

Appln. No. 10/634,682

24. (New) A pyrimidinyl compound as claimed in claim 23, wherein the compound is the hydrochloride salt of 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile.
25. (New) A pyrimidinyl compound as claimed in claim 1, wherein the compound is a quaternary amine of 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile.
26. (New) A pharmaceutical composition as claimed in claim 3, wherein the pharmaceutical composition is a tablet.
27. (New) A pharmaceutical composition as claimed in claim 3, wherein the effective amount is between 1 to 1000 mg of active ingredient per unit dosage form.
28. (New) A pharmaceutical composition as claimed in claim 29, wherein the effective amount is between 5 and 200 mg of active ingredient per unit dosage form.
29. (New) A tablet as claimed in claim 26, wherein the effective amount is between 1 to 1000 mg of active ingredient.
30. (New) A tablet as claimed in claim 29, wherein the effective amount is between 5 to 200 mg of active ingredient.
31. (New) A method of treating subjects suffering from HIV-1 (Human Immunodeficiency Virus) infection that have acquired resistance to art-known non-nucleoside reverse transcriptase inhibitors comprising administering to the subject an effective amount of a compound according to any of claims 1 or 2.
32. (New) A method of treating subjects suffering from HIV-1 (Human Immunodeficiency Virus) infection that have acquired resistance to art-known non-nucleoside reverse transcriptase inhibitors comprising administering to the subject an effective amount of a combination comprising a pyrimidinyl compound according to any of claims 1 or 2 and an

Appln. No. 10/634,682

antiretroviral compound, wherein said antiretroviral compound comprises at least one of a nucleoside reverse transcriptase inhibitor, a non-nucleoside reverse transcriptase inhibitor, a TIBO compound, an  $\alpha$ -APA compound, a TAT-inhibitor, a protease inhibitor, an immunomodulating agent, and mixtures thereof, and wherein said pyrimidinyI compound and said antiretroviral compound are administered simultaneously, separately or sequentially.